 |
 |
| FOR MORE INFORMATION: | Company Contact: | |
| Jacqueline Lemke | ||
| President & CEO and CFO | ||
| Phone: 765.497.5829 | ||
| jlemke@BASinc.com | ||
| Agency Contact: | ||
| Neil Berkman | ||
| Berkman Associates | ||
| Phone: 310.477.3118 | ||
| info@berkmanassociates.com |
BASi Reports Second Quarter Results
WEST LAFAYETTE, IN -- May 15, 2014 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced financial results for the second quarter and first six months of fiscal 2014.
| Second Quarter Highlights | ||
| ● | Revenue up 14.7% versus last fiscal year's second quarter | |
| ● | Gross profit up 59.9% | |
| ● | Gross margin up 9.6 percentage points | |
| ● | Operating income increased to $105,000 versus an operating loss. | |
| First Half Highlights | ||
| ● | Revenue up 10.7% versus last fiscal year's first half | |
| ● | Operating income up 92.9% | |
| ● | Cash provided by operations up 99.8% to $1,005,000 | |
| ● | EBITDA up 5.5% to $1,416,000 | |
BASi President & CEO and CFO Jacqueline Lemke said, "The trend of steadily improving operating performance at BASi continued in the second quarter. The improvement in our financial results was instrumental in our establishing a new $7,500,000 credit facility this month with The Huntington National Bank, consisting of a $5,500,000 term loan at LIBOR plus 325 basis points, and a $2,000,000 revolving line of credit at LIBOR plus 300 basis points. With substantially more favorable terms than the long-term debt and line of credit it replaces, this new credit facility lowers BASi's borrowing costs and enhances our ability to implement our growth plan. In addition to these tangible benefits, our new credit facility is a strong vote of confidence in BASi's future, and we are pleased that The Huntington National Bank has recognized our progress. We intend to use our new term loan facility to pay off the current portion of our long-term debt, which amounted to approximately $4,953,000 at March 31, 2014.
"We are leveraging our existing laboratory capacity and an incremental investment in people and skills to drive growth. We took steps to upgrade BASi's executive leadership during the second quarter, as we continue building a management team with the depth, experience and dedication to take the company to the next level.
"Our focus on BASi's established strengths in specialty assay and drug discovery, regulatory excellence, and our market-changing Culex® NxT automated sampling system is generating an increase in orders in our traditional businesses and creating opportunities for us to win contracts in new areas such as discovery work on stem cell therapies and related pre-clinical work. This expansion of our portfolio of services is especially important as we work to increase our book of business with the current generation of smaller, specialty drug development organizations that generally do not have the extensive scientific and regulatory capabilities required to move a drug candidate through the arduous FDA approval process. We are seeking to develop a sustainable competitive advantage by balancing the requirements of our large pharmaceutical company clients with a higher touch, full service approach for smaller biotech accounts."
Second Quarter Results
For the three months ended March 31, 2014, revenue increased 14.7% to $5,912,000 compared to $5,156,000 for the second quarter of fiscal 2013. Gross profit increased to $2,012,000, or 34.0% of revenue, compared to $1,258,000, or 24.4% of revenue, during the comparable period last year.
The net loss for the second quarter of fiscal 2014 was $219,000, or $0.03 per share, compared to a net loss for the second quarter of fiscal 2013 of $311,000, or $0.04 per share.
The net loss for the second fiscal quarter was affected by a non-cash increase in the fair value of the warrant liability of $200,000. Excluding this charge, the non-GAAP net loss for the second quarter of fiscal 2014 was $19,000, or $0.00 per share. For the second quarter of fiscal 2013, the net loss included a non-cash increase in the fair value of the warrant liability of $142,000. Excluding this charge, the non-GAAP net loss for the second quarter of fiscal 2013 was $169,000, or $0.02 per basic and diluted share.
Operating expenses for the second quarter of fiscal 2014 increased to $1,907,000 compared to $1,267,000 during the second quarter of fiscal 2013, primarily due to planned increases in selling and R&D expenses. Operating income increased to $105,000 compared to an operating loss of $9,000 for last fiscal year's second quarter.
Service revenue increased 23.4% to $4,526,000 for the second quarter of fiscal 2014 compared to $3,667,000 for the prior fiscal year period primarily due to higher toxicology and bioanalytical revenues offset slightly by lower pharmaceutical analysis revenues.
Product revenue decreased 6.9% for the second quarter of fiscal 2014 to $1,386,000 compared to $1,489,000 during the second quarter of fiscal 2013, primarily due to expected upgrades postponed until the third quarter of fiscal 2014.
EBITDA for the second quarter of fiscal 2014 was $504,000 compared to EBITDA for the second quarter of fiscal 2013 of $490,000.
First Half Results
For the six months ended March 31, 2014, revenue increased 10.7% to $12,132,000 compared to $10,960,000 for the first six months of fiscal 2013. Gross margin for this year's first half increased 33.5% to $4,157,000, or 34.3% of revenue, compared to $3,114,000, or 28.4% of revenue, for the same period of the prior fiscal year. Operating income increased 92.9% to $567,000 compared to $294,000 a year earlier.
The net loss for the first six months of fiscal 2014 of $881,000, or $0.11 per share, included an increase in the fair value of the warrant liability of $1,161,000. Excluding this charge, non-GAAP net income for the first six months of fiscal 2014 was $280,000, or $0.04 per basic and diluted share. For the first six months of fiscal 2013, the net loss of $55,000, or $0.01 per basic and diluted share, included an increase in the fair value of the warrant liability of $25,000. Excluding this charge, the non-GAAP net loss for the first six months of fiscal 2013 was $30,000, or $0.00 per basic and diluted share.
EBITDA for the first six months of fiscal 2014 was $1,416,000 compared to EBITDA for the first six months of fiscal 2013 of $1,342,000.
Earnings Conference Call
BASi has scheduled a conference call at 11:00 a.m. EDT this morning to discuss its results for the quarter. To participate in the call, dial 866.713.8563, passcode #24051454 at least five minutes before the start of the call. A simultaneous webcast may be accessed from the Investors tab at www.BASInc.com. The webcast will be available for replay after 2:00 p.m. EST at this same Internet address. For a telephone replay, dial 888.286.8010, passcode #60437922 after 2:00 p.m. EST.
Non-GAAP to GAAP Reconciliation
This press release contains financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). The non-GAAP financial measures are net income excluding the income or expense of the change in the warrant liability, and EBITDA for the first two quarters of fiscal 2014 and 2013. EBITDA refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation, and amortization. EBITDA may also exclude certain non-cash or one-time expenses, such as stock-based compensation and the income or expense from the change in the warrant liability.
The non-GAAP financial information should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management, however, believes that these non-GAAP financial measures, when used in conjunction with the results presented in accordance with GAAP, may provide a more complete understanding of the Company's results and may facilitate a fuller analysis of the Company's results, particularly in evaluating performance from one period to another. Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of results and to illustrate the results giving effect to the non-GAAP adjustments shown in the reconciliation. Management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
[SEE BELOW FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts)(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Service revenue | $ | 4,526 | $ | 3,667 | $ | 9,442 | $ | 8,337 | ||||||||
| Product revenue | 1,386 | 1,489 | 2,690 | 2,623 | ||||||||||||
| Total revenue | 5,912 | 5,156 | 12,132 | 10,960 | ||||||||||||
| Cost of service revenue | 3,330 | 3,230 | 6,653 | 6,612 | ||||||||||||
| Cost of product revenue | 570 | 668 | 1,322 | 1,234 | ||||||||||||
| Total cost of revenue | 3,900 | 3,898 | 7,975 | 7,846 | ||||||||||||
| Gross profit | 2,012 | 1,258 | 4,157 | 3,114 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling | 479 | 292 | 916 | 662 | ||||||||||||
| Research and development | 170 | 123 | 313 | 208 | ||||||||||||
| General and administrative | 1,258 | 852 | 2,361 | 1,950 | ||||||||||||
| Total operating expenses | 1,907 | 1,267 | 3,590 | 2,820 | ||||||||||||
| Operating income (loss) | 105 | (9 | ) | 567 | 294 | |||||||||||
| Interest expense | (121 | ) | (163 | ) | (285 | ) | (329 | ) | ||||||||
| Change in fair value of warrant liability increase | (200 | ) | (142 | ) | (1,161 | ) | (25 | ) | ||||||||
| Other income | 4 | 3 | 5 | 5 | ||||||||||||
| Loss before income taxes | (212 | ) | (311 | ) | (874 | ) | (55 | ) | ||||||||
| Income taxes | 7 | -- | 7 | -- | ||||||||||||
| Net loss | $ | (219 | ) | $ | (311 | ) | $ | (881 | ) | $ | (55 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustment | (8 | ) | 46 | (34 | ) | 55 | ||||||||||
| Comprehensive loss | $ | (227 | ) | $ | (265 | ) | $ | (915 | ) | $ | -- | |||||
| Basic net loss per share | $ | (0.03 | ) | $ | (0.04 | ) | $ | (0.11 | ) | $ | (0.01 | ) | ||||
| Diluted net loss per share | $ | (0.03 | ) | $ | (0.04 | ) | $ | (0.11 | ) | $ | (0.01 | ) | ||||
| Weighted common shares outstanding: | ||||||||||||||||
| Basic | 7,964 | 7,657 | 7,848 | 7,648 | ||||||||||||
| Diluted | 7,964 | 7,657 | 7,848 | 7,648 | ||||||||||||
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
| Mar. 31, | Sep. 30, | |||||||
| 2014 | 2013 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 379 | $ | 1,304 | ||||
| Accounts receivable | ||||||||
| Trade, net | 2,735 | 3, 621 | ||||||
| Unbilled revenues and other | 1,135 | 691 | ||||||
| Inventories | 1,507 | 1,379 | ||||||
| Prepaid expenses | 761 | 238 | ||||||
| Total current assets | 6,517 | 7,233 | ||||||
| Property and equipment, net | 16,267 | 16,913 | ||||||
| Goodwill | 1,383 | 1,383 | ||||||
| Debt issue costs | 42 | 21 | ||||||
| Other assets | 43 | 47 | ||||||
| Total assets | $ | 24,252 | $ | 25,597 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,363 | $ | 3,584 | ||||
| Accrued expenses | 1,657 | 1,689 | ||||||
| Customer advances | 3,087 | 2,815 | ||||||
| Income tax accruals | 22 | 30 | ||||||
| Revolving line of credit | -- | 1,415 | ||||||
| Fair value of warrant liability | 934 | 612 | ||||||
| Current portion of capital lease obligation | 276 | 268 | ||||||
| Current portion of long-term debt | 4,953 | 613 | ||||||
| Total current liabilities | 14,292 | 11,026 | ||||||
| Capital lease obligation, less current portion | 331 | 471 | ||||||
| Long-term debt, less current portion | -- | 4,641 | ||||||
| Total liabilities | 14,623 | 16,138 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Preferred shares, authorized 1,000,000 shares, no par value: 1,185 | ||||||||
| Series A shares at $1,000 stated value issued and outstanding | ||||||||
| at March 31, 2014 and 1,335 at September 30, 2013 | 1,185 | 1,335 | ||||||
| Common shares, no par value: authorized 19,000,000 shares; 8,057,267 issued | ||||||||
| and outstanding at March 31, 2014 and 7,703,891 at September 30, 2013 | 1,976 | 1,887 | ||||||
| Additional paid-in capital | 21,071 | 19,925 | ||||||
| Accumulated deficit | (14,601 | ) | (13,720 | ) | ||||
| Accumulated other comprehensive income | (2 | ) | 32 | |||||
| Total shareholders’ equity | 9,629 | 9,459 | ||||||
| Total liabilities and shareholders’ equity | $ | 24,252 | $ | 25,597 | ||||
BIOANALYTICAL SYSTEMS, INC.
RECONCILIATION OF GAAP TO NONGAAP EARNINGS
(In thousands)(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| GAAP Net income (loss) | $ | (219 | ) | $ | (311 | ) | $ | (881 | ) | $ | (55 | ) | ||||
| Addback: Interest expense | 121 | 163 | 285 | 329 | ||||||||||||
| Income taxes | 7 | -- | 7 | -- | ||||||||||||
| Depreciation and amortization | 397 | 435 | 799 | 908 | ||||||||||||
| Change in fair value of warrant liability | 200 | 142 | 1,161 | 25 | ||||||||||||
| Stock option expense | (2 | ) | 61 | 45 | 135 | |||||||||||
| NONGAAP EBITDA | $ | 504 | $ | 490 | $ | 1,416 | $ | 1,342 | ||||||||
EBITDA - Earnings before interest, taxes, depreciation, amortization, stock option expenses and the change in the fair value of warrant liability.